- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06603571
En studie for å undersøke vektkontroll med LY3841136 og Tirzepatide (LY3298176), alene eller i kombinasjon, hos voksne deltakere med fedme eller overvekt med type 2-diabetes
En fase 2, parallellgruppe, dobbeltblind, placebokontrollert studie for å undersøke vektkontroll med LY3841136 og tirzepatid, alene eller i kombinasjon, hos voksne deltakere med fedme eller overvekt med type 2-diabetes
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136 for chronic weight management alone or in combination with Tirzepatide across a wide dose range in participants with Type 2 Diabetes. Participation in the study will last about 64 weeks.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
-
Buenos Aires, Argentina, C1425AGC
- Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada
-
Buenos Aires, Argentina, C1056ABI
- Centro de Investigaciones Metabólicas (CINME)
-
Buenos Aires, Argentina, C1120AAC
- Centro Médico Viamonte
-
Buenos Aires, Argentina, C1405BUB
- Consultorio de Investigación Clínica EMO SRL
-
-
-
-
Arizona
-
Chandler, Arizona, Forente stater, 85225
- The Institute for Liver Health II dba Arizona Clinical Trials - Mesa
-
Phoenix, Arizona, Forente stater, 85032
- HOPE Research Institute
-
Scottsdale, Arizona, Forente stater, 85260
- Headlands Research - Scottsdale
-
Tucson, Arizona, Forente stater, 85712
- The Institute for Liver Health II dba Arizona Liver Health-Tucson
-
-
California
-
Greenbrae, California, Forente stater, 94904
- NorCal Medical Research, Inc
-
Huntington Park, California, Forente stater, 90255
- Velocity Clinical Research, Huntington Park
-
Rolling Hills Estates, California, Forente stater, 90274
- Peninsula Research Associates
-
Walnut Creek, California, Forente stater, 94598
- Diablo Clinical Research, Inc.
-
-
Connecticut
-
Stamford, Connecticut, Forente stater, 06905
- Stamford Therapeutics Consortium
-
-
Florida
-
Fleming Island, Florida, Forente stater, 32003
- Northeast Research Institute (NERI)
-
Hialeah, Florida, Forente stater, 33012
- Indago Research & Health Center, Inc
-
Miami, Florida, Forente stater, 33165
- New Horizon Research Center
-
New Port Richey, Florida, Forente stater, 34652
- Suncoast Clinical Research, Inc.
-
Orlando, Florida, Forente stater, 32803
- Charter Research - Winter Park
-
The Villages, Florida, Forente stater, 32162
- Charter Research - Lady Lake
-
-
Idaho
-
Ammon, Idaho, Forente stater, 83406
- Medical Research Partners
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60640
- Great Lakes Clinical Trials - Andersonville
-
Chicago, Illinois, Forente stater, 60640
- Great Lakes Clinical Trials - Ravenswood
-
Skokie, Illinois, Forente stater, 60077
- NorthShore University Health System
-
-
Iowa
-
West Des Moines, Iowa, Forente stater, 50266
- Iowa Diabetes and Endocrinology Research Center
-
-
Kansas
-
Topeka, Kansas, Forente stater, 66606
- Cotton O'Neil Diabetes & Endocrinology
-
-
Massachusetts
-
Needham, Massachusetts, Forente stater, 02492
- Knownwell
-
New Bedford, Massachusetts, Forente stater, 02740
- Lucida Clinical Trials
-
-
Michigan
-
Southfield, Michigan, Forente stater, 48034
- Headlands Research - Detroit
-
Troy, Michigan, Forente stater, 48098
- Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
-
-
Missouri
-
City of Saint Peters, Missouri, Forente stater, 63303
- StudyMetrix Research
-
Springfield, Missouri, Forente stater, 65807
- Clinvest Headlands Llc
-
-
Nevada
-
Las Vegas, Nevada, Forente stater, 89128
- Las Vegas Medical Research
-
-
New York
-
Amherst, New York, Forente stater, 14226
- Dent Neurologic Institute
-
East Syracuse, New York, Forente stater, 13057
- Velocity Clinical Research, Syracuse
-
Port Jefferson Station, New York, Forente stater, 11776
- North Suffolk Neurology
-
Rochester, New York, Forente stater, 14609
- Rochester Clinical Research, LLC
-
-
North Carolina
-
Greensboro, North Carolina, Forente stater, 27405
- Medication Management
-
Monroe, North Carolina, Forente stater, 28112
- Monroe Biomedical Research
-
Morehead City, North Carolina, Forente stater, 28557
- Lucas Research, Inc
-
New Bern, North Carolina, Forente stater, 28562
- Lucas Research, Inc.
-
-
Ohio
-
Cincinnati, Ohio, Forente stater, 45212
- CTI Clinical Research Center
-
-
South Carolina
-
Greenville, South Carolina, Forente stater, 29607
- Tribe Clinical Research, LLC
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37211
- Quality Medical Research
-
-
Texas
-
Austin, Texas, Forente stater, 78745
- IMA Clinical Research Austin
-
Dallas, Texas, Forente stater, 75230
- Velocity Clinical Research, Dallas
-
Dallas, Texas, Forente stater, 75251
- FutureSearch Trials of Dallas
-
Houston, Texas, Forente stater, 77079
- PlanIt Research, PLLC
-
San Antonio, Texas, Forente stater, 78240
- Endeavor Clinical Trials
-
San Antonio, Texas, Forente stater, 78229
- Tekton Research - Fredericksburg Road
-
Weslaco, Texas, Forente stater, 78596
- Texas Valley Clinical Research
-
-
Virginia
-
Danville, Virginia, Forente stater, 24541
- Spectrum Medical, Inc.
-
-
Washington
-
Wenatchee, Washington, Forente stater, 98801
- Central Washington Health Services Association d/b/a Confluence Health
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
W8M-MC-LAA2
- Have a Body Mass Index (BMI) of ≥27 kilograms per square meter (kg/m²)
- Have Type 2 Diabetes
- Have a HbA1c ≥7.0 % (53 millimoles/mole (mmol/mol)) to ≤10.5% (91 mmol/mol) and treated with diet and exercise alone or with a stable dose of metformin (and not more than the locally approved dose) with or without a sodium-glucose cotransporter 2 (SGLT2) inhibitor for at least 3 months prior to screening
W8M-MC-CWMM:
- Have had a stable body weight for the 3 months prior to randomization (<5% body weight gain and/or loss)
Exclusion Criteria:
W8M-MC-LAA2
-
Have a history of severe hypoglycemia or hypoglycemia unawareness within the last 6 months prior to screening
-
Have an on-going or history of bradyarrhythmia and/or sinus bradycardia
-
Have an elevated resting pulse rate (mean >100 beats per minute (bpm)) or reduced resting pulse rate (mean <60 bpm) at screening
-
Have any of the following cardiovascular conditions within 6 months prior to screening:
- acute myocardial infarction
- cerebrovascular accident (stroke)
- unstable angina, or
- hospitalization due to congestive heart failure
-
Have renal impairment measured as estimated glomerular filtration rate (eGFR) <45 milliliters per minute (mL/min)/1.73 m2
-
Have a history of acute or chronic pancreatitis
-
Have fasting triglycerides >500 milligrams per deciliter (mg/dL) (5.7 mmol/L) at screening
-
All concomitant medications should be at a stable dose for at least 3 months prior to screening
W8M-MC-CWMM
- Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed >1 year prior to screening.
- Have type 1 diabetes mellitus, latent autoimmune diabetes in adults, or history of ketoacidosis or hyperosmolar coma.
- Have poorly controlled hypertension.
- Have a history of symptomatic gallbladder disease within the past 2 years
- Have signs and symptoms of any liver disease other than nonalcoholic fatty liver disease.
- Have a lifetime history of suicide attempts.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: LY3841136 Dose 1
Participants will receive LY3841136 subcutaneously (SC) |
Administered SC |
|
Eksperimentell: LY3841136 Dose 2
Participants will receive LY3841136 SC |
Administered SC |
|
Eksperimentell: LY3841136 Dose 3
Participants will receive LY3841136 SC |
Administered SC |
|
Eksperimentell: LY3841136 Dose 1 + Tirzepatide Dose 1
Participants will receive LY3841136 SC and Tirzepatide SC |
Administered SC Administered SC |
|
Eksperimentell: LY3841136 Dose 2 + Tirzepatide Dose 1
Participants will receive LY3841136 SC and Tirzepatide SC |
Administered SC Administered SC |
|
Eksperimentell: LY3841136 Dose 2 + Tirzepatide Dose 2
Participants will receive LY3841136 SC and Tirzepatide SC |
Administered SC Administered SC |
|
Eksperimentell: LY3841136 Dose 3 + Tirzepatide Dose 3
Participants will receive LY3841136 SC and Tirzepatide SC |
Administered SC Administered SC |
|
Aktiv komparator: Tirzepatide Dose 3
Participants will receive Tirzepatide SC |
Administered SC |
|
Eksperimentell: LY3841136 Dose 2 + Tirzepatide Dose 3
Participants will receive LY3841136 SC and Tirzepatide SC |
Administered SC Administered SC |
|
Placebo komparator: Placebo
Participants will receive placebo administered SC. |
Administered SC |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Prosentvis endring fra baseline i kroppsvekt
Tidsramme: Grunnlinje, uke 48
|
Grunnlinje, uke 48
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Prosentandel av deltakere som oppnår ≥5 % kroppsvektreduksjon
Tidsramme: Uke 48
|
Uke 48
|
|
Prosentandel av deltakere som oppnår ≥10 % kroppsvektreduksjon
Tidsramme: Uke 48
|
Uke 48
|
|
Endring fra baseline i kroppsvekt
Tidsramme: Grunnlinje, uke 48
|
Grunnlinje, uke 48
|
|
Endring fra baseline i hemoglobin A1c (HbA1c)
Tidsramme: Grunnlinje, uke 48
|
Grunnlinje, uke 48
|
|
Farmakokinetikk (PK): Area Under the Curve (AUC) av LY3841136
Tidsramme: Grunnlinje, uke 48
|
Grunnlinje, uke 48
|
|
PK: Maksimal konsentrasjon (Cmax) av LY3841136
Tidsramme: Grunnlinje, uke 48
|
Grunnlinje, uke 48
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Sykdommer i det endokrine systemet
- Ernæringsforstyrrelser
- Metabolske sykdommer
- Overernæring
- Kroppsvekt
- Glukosemetabolismeforstyrrelser
- Sukkersyke
- Patologiske tilstander, tegn og symptomer
- Ernæringsmessige og metabolske sykdommer
- Tegn og symptomer
- Overvektig
- Overvekt
- Diabetes mellitus, type 2
- Aminosyrer, peptider og proteiner
- Proteiner
- Glukagonlignende peptid-1 reseptor
- Glukagonlignende peptidreseptorer
- Reseptorer, G-protein-koblet
- Reseptorer, celleoverflate
- Membranproteiner
- Reseptorer, gastrointestinal hormon
- Reseptorer, peptid
- Tirzepatid
Andre studie-ID-numre
- 18809
- W8M-MC-LAA2 (Annen identifikator: Eli Lilly and Company)
- W8M-MC-CWMM Master Protocol (Annen identifikator: Eli Lilly and Company)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD-delingstidsramme
Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Tilgangskriterier for IPD-deling
A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- CSR
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .